Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation status
Michael C. Heinrich(VA Portland Health Care System), G. D. Demetri(Brigham and Women's Hospital), Charles M. Baum(Brigham and Women's Hospital), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Xin Huang(Lineage Cell Therapeutics (United States)), Jonathan A. Fletcher(Harvard University), Christopher L. Corless(Oregon Health & Science University), Cristina Antonescu(Brigham and Women's Hospital), Christopher D.�M. Fletcher(Brigham and Women's Hospital)
Cited by 83
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835